Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

14. Januar 2026 10:39 ET | Quelle: USA News Group

The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive...
13. Januar 2026 16:05 ET | Quelle: TheRas, Inc. (d/b/a BBOT)

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway...
13. Januar 2026 08:45 ET | Quelle: Propanc Biopharma, Inc.

Propanc Biopharma Provides Shareholder Update

In this update, Mr. Nathanielsz highlights the significant progress achieved during 2025 and outlines the Company’s ambitious plans for 2026.
12. Januar 2026 10:14 ET | Quelle: Equity Insider

The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff

VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The biotechnology sector is entering a high-stakes survival sprint as major pharmaceutical giants...
12. Januar 2026 10:00 ET | Quelle: Biocartis NV

Press Release Biocartis NV: Biocartis to collaborate with Mayo Clinic on breast cancer gene signatures

PRESS RELEASE, 01/12/2026, 10:00 EST Biocartis to collaborate with Mayo Clinic on breast cancer gene signatures Itasca, IL, US, 12 January 2026 – Biocartis announced today that it has entered into a...
12. Januar 2026 07:00 ET | Quelle: Precede Biosciences, Inc.

Precede Biosciences Secures $83.5M in Total Financing to Scale Next-Generation Precision Diagnostics Platform

Precede Biosciences Secures $83.5M in Total Financing to Scale Next-Generation Precision Diagnostics Platform
12. Januar 2026 06:45 ET | Quelle: BioNTech SE

BioNTech präsentiert auf der 44. J.P. Morgan Healthcare-Konferenz Updates zur Geschäftsentwicklung und Schwerpunkte für das Jahr 2026

2026 soll für BioNTech ein Jahr mit zahlreichen wertrelevanten Meilensteinen (Katalysatoren) werden, unter anderem durch weitere Fortschritte bei Pipeline-Kandidaten, die sich bereits in der späten...
12. Januar 2026 06:45 ET | Quelle: BioNTech SE

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

2026 poised to be a catalyst-rich year for BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapiesExpected 2026...
09. Januar 2026 10:30 ET | Quelle: Novartis Pharma AG

Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment

New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern USPurpose-built facility will strengthen Novartis RLT...
09. Januar 2026 10:30 ET | Quelle: Novartis Pharma AG

Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment

New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern USPurpose-built facility will strengthen Novartis RLT...

Nächste Seite